Impact News +++ Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of... (GlobeNewswire EN) +++ ASP ISOTOPES Aktie +4,38%

DAIICHI SANKYO Aktie

>DAIICHI SANKYO Aktienkurs

21.25 EUR +1.7% (Tradegate)

Ask: 21.56 EUR / 232 Stück

Bid: 21.25 EUR / 236 Stück

Tagesumsatz: 926 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>DAIICHI SANKYO Performance

1 Woche: +2,2%

1 Monat: -1,6%

3 Monate: -5,0%

6 Monate: -8,5%

1 Jahr: -41,6%

laufendes Jahr: -23,0%

>DAIICHI SANKYO Aktie

Name:

DAIICHI SANKYO CO. LTD

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3475350009 / A0F57T

Symbol/ Ticker:

D4S (Frankfurt)

Kürzel:

FRA:D4S, ETR:D4S, D4S:GR

Index:

Nikkei225

Webseite:

https://www.daiichisankyo..

Profil:

Daiichi Sankyo Co., Ltd. is a Japan-based pharmace..
>Volltext..

Marktkapitalisierung:

38798.64 Mio. EUR

Unternehmenswert:

36613.98 Mio. EUR

Umsatz:

11398.55 Mio. EUR

EBITDA:

2391.34 Mio. EUR

Nettogewinn:

1752.25 Mio. EUR

Gewinn je Aktie:

0.93 EUR

Schulden:

1191.78 Mio. EUR

Liquide Mittel:

3401.17 Mio. EUR

Operativer Cashflow:

754.01 Mio. EUR

Bargeldquote:

0.72

Umsatzwachstum:

15.88%

Gewinnwachstum:

31.17%

Dividende je Aktie:

0.37 EUR

Dividendenrendite:

1.66%

Dividendenschätzung:

2.15%

Div. Historie:

28.03.25 - 0.18486601€
27.09.24 - 0.18786001€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

DAIICHI SANKYO

Letzte Datenerhebung:

08.09.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 1850.94 Mio. St.

Frei handelbar: 87.89%

Leerverk. Aktien: -

Rückkaufquote: 3.95%

Mitarbeiter: 19765

Umsatz/Mitarb.: 0.54 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 57.46%

Bewertung:

KGV: 22.17

KGV lG: 20.48

KUV: 3.55

KBV: 4.09

PEG-Ratio: 0.74

EV/EBITDA: 15.31

Rentabilität:

Bruttomarge: 78.54%

Gewinnmarge: 15.37%

Operative Marge: 17.35%

Managementeffizenz:

Gesamtkaprendite: 8.58%

Eigenkaprendite: 17.93%

>Peer Group

Es sind 53 Aktien bekannt.

>DAIICHI SANKYO Chart & Kurs - Tradegate

>DAIICHI SANKYO News

08.09.25 - 07:42	Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstra......

21.08.25 - 10:48	Japan′s Daiichi Sankyo Shares Drop After Discounted Block Trades (Bloomberg)
	Daiichi Sankyo Co. shares dropped the most in three months following a series of discounted block trades in the Japanese pharmaceutical company....

18.08.25 - 14:01	Daiichi Sankyo Announces Breakthrough Therapy Designation For Ifinatamab Deruxtecan (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo announced that Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stag......

31.07.25 - 12:54	Daiichi Sankyo reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 12:24	Daiichi Sankyo Q1 Profit Edges Up, Revenues Rise; Confirms FY Outlook (AFX)
	TOKYO (dpa-AFX) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) reported Thursday first-quarter profit attributable to shareholders of 85.50 billion Japanese yen, up 0.1 percent from......

18.07.25 - 14:00	Daiichi Sankyo and AstraZeneca′s Enhertu gains breakthrough therapy status (PBR)
	This designation is for its use in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. The FDA's decision was The post Daiichi Sankyo and AstraZeneca's Enhertu gains breakthrough therapy status appeared first on Pharmaceutical Business review....

17.07.25 - 17:30	AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.07.25 - 06:00	Research: UBS Lists Asian Stocks w/ 2Q Results Expected to Beat Mkt Consensus (Table) (AAStocks)
	StockFUYAO GLASS (03606.HK) KUAISHOU-W (01024.HK) HANSOH PHARMA (03692.HK) TSMC (2330.TW) SK hynix(000660.KS) Samsung Electronics(005930. KS) Daiichi Sankyo(4568.JP) BAOFENG ENERGY(600989.SH) Komatsu(6301.JP) FOOD & LIFE(3563.JP) Wistron(3231.TW) Makita(6586.JP) New Oriental Education & Technology Group(EDU. US) Multi Co......

24.06.25 - 10:30	AstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M (AAStocks)
	AstraZeneca (AZN.US) and its partner Daiichi Sankyo (4568.JP) have received approval from US regulators for their precision medicine Datroway, which is intended for previously treated patients with advanced non-small cell lung cancer. This marks the first time such a therapy has been approved in the US for lung cancer treatment.......

24.06.25 - 08:54	AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer (AFX)
	LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-deve......

17.06.25 - 13:06	Targeted cancer drugs may replace chemo for some patients — and drugmakers say theyre getting closer (CNBC)
	Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety....

02.06.25 - 16:12	AstraZeneca Reports Encouraging Data For Enhertu As 1st-line Treatment Of HER2+ Breast Cancer (AFX)
	LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) Monday announced positive results from the DESTINY-Breast09 Phase III study evaluating Enhertu, co-developed with Daiichi Sankyo Company Limited (DSKYF.P......

02.06.25 - 15:06	Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study (Bloomberg)
	AstraZeneca Plc and Daiichi Sankyo Co.'s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine....

31.05.25 - 16:42	AstraZeneca And Daiichi Sankyo′s ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial (AFX)
	LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstra......

29.05.25 - 14:30	Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan (AFX)
	KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited......

29.05.25 - 14:00	Merck, Daiichi Sankyo pull marketing application for lung cancer therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.05.25 - 22:18	Merck And Daiichi Sankyo Dose First Patient In Phase 3 Trial For Advanced Esophageal Cancer (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), in collaboration with Daiichi Sankyo, Monday has announced that the first patient has been dosed in the Phase 3 IDeate-Esophageal01 trial. This......

07.05.25 - 14:24	AstraZeneca, Daiichi Sankyo Report Positive Results From DESTINY-Breast11 Phase III Study Of Enhertu (AFX)
	LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) and Daiichi Sankyo Company Limited (DSKYF.PK) Wednesday reported positive results from the DESTINY-Breast11 Phase III study of Enhertu. The study met its......

07.05.25 - 08:36

Enhertu improved pCR in early-stage breast cancer (Cision)

07 May 2025 Enhertufollowed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel,...

25.04.25 - 13:12	Daiichi Sankyo repors FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mittelmaß . . . Die übliche Ballungszone des menschlichen Geistes. - Julio Cortázar

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram